Humanigen, Inc. (HGEN): Price and Financial Metrics
GET POWR RATINGS... FREE!
HGEN Stock Summary
- The ratio of debt to operating expenses for HUMANIGEN INC is higher than it is for about only 0.44% of US stocks.
- With a year-over-year growth in debt of -100%, HUMANIGEN INC's debt growth rate surpasses only 0% of about US stocks.
- The volatility of HUMANIGEN INC's share price is greater than that of 99.76% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to HUMANIGEN INC are ARAV, CLLS, ABUS, IVA, and RVMD.
- HGEN's SEC filings can be seen here. And to visit HUMANIGEN INC's official web site, go to www.humanigen.com.
HGEN Valuation Summary
- In comparison to the median Healthcare stock, HGEN's price/sales ratio is 184.21% higher, now standing at 5.4.
- HGEN's EV/EBIT ratio has moved up 6 over the prior 123 months.
Below are key valuation metrics over time for HGEN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HGEN | 2023-03-17 | 5.4 | -0.3 | -0.2 | 0.1 |
| HGEN | 2023-03-16 | 5.6 | -0.4 | -0.2 | 0.1 |
| HGEN | 2023-03-15 | 5.7 | -0.4 | -0.2 | 0.1 |
| HGEN | 2023-03-14 | 5.2 | -0.3 | -0.2 | 0.1 |
| HGEN | 2023-03-13 | 5.3 | -0.3 | -0.2 | 0.1 |
| HGEN | 2023-03-10 | 5.0 | -0.3 | -0.2 | 0.1 |
HGEN Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at 62.34%.
- Its 4 year cash and equivalents growth rate is now at -96.64%.
- Its year over year cash and equivalents growth rate is now at -25.78%.
The table below shows HGEN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 3.33 | -94.387 | -108.66 |
| 2022-06-30 | 4.145 | -125.08 | -151.706 |
| 2022-03-31 | 4.145 | -167.663 | -192.36 |
| 2021-12-31 | 3.595 | -184.045 | -236.649 |
| 2021-09-30 | 2.87 | -175.481 | -235.404 |
| 2021-06-30 | 1.834 | -151.022 | -199.416 |
HGEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HGEN has a Quality Grade of C, ranking ahead of 29.47% of graded US stocks.
- HGEN's asset turnover comes in at 0.019 -- ranking 371st of 682 Pharmaceutical Products stocks.
- ZSAN, ARMP, and AGRX are the stocks whose asset turnover ratios are most correlated with HGEN.
The table below shows HGEN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.019 | 1 | 9.745 |
| 2021-03-31 | 0.011 | 1 | 9.024 |
| 2020-12-31 | 0.006 | 1 | 6.758 |
| 2020-09-30 | 0.000 | NA | 5.896 |
| 2020-06-30 | 0.000 | NA | 3.998 |
| 2020-03-31 | 0.000 | NA | 1.549 |
HGEN Price Target
For more insight on analysts targets of HGEN, see our HGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $21.13 | Average Broker Recommendation | 1.67 (Moderate Buy) |
HGEN Stock Price Chart Interactive Chart >
HGEN Price/Volume Stats
| Current price | $0.14 | 52-week high | $3.47 |
| Prev. close | $0.13 | 52-week low | $0.09 |
| Day low | $0.13 | Volume | 321,400 |
| Day high | $0.14 | Avg. volume | 3,502,098 |
| 50-day MA | $0.16 | Dividend yield | N/A |
| 200-day MA | $0.44 | Market Cap | 14.20M |
Humanigen, Inc. (HGEN) Company Bio
Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Latest HGEN News From Around the Web
Below are the latest news stories about HUMANIGEN INC that investors may wish to consider to help them evaluate HGEN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday! |
Humanigen Reports Third Quarter 2022 Financial ResultsShort Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strateg |
Humanigen Announces Participation and Presentation at Jefferies London Healthcare ConferenceShort Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinica |
Humanigen Announces Retention of SC&H Capital as Financial AdvisorShort Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affiliate of SC&H Group, to advise Humanigen on exploration of strategic options. SC&H is an investment banking and advisory firm providing merger and acquisition (M&A), financial restructuring and related business a |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, investor! |
HGEN Price Returns
| 1-mo | -9.68% |
| 3-mo | N/A |
| 6-mo | -13.69% |
| 1-year | -95.69% |
| 3-year | -97.83% |
| 5-year | -95.69% |
| YTD | 16.67% |
| 2022 | -96.77% |
| 2021 | -78.74% |
| 2020 | 617.95% |
| 2019 | -30.36% |
| 2018 | 73.91% |
Loading social stream, please wait...